From the Journals

Patients at risk for Barrett’s esophagus rarely screened


 

FROM AMERICAN JOURNAL OF GASTROENTEROLOGY

Less-invasive screening options

Fear of endoscopy may be another issue.

In their survey, Dr. Kolb and colleagues found that 20% of respondents reported fear of discomfort with endoscopy as a barrier to completing screening.

But less-invasive screening options are increasingly available or in development.

This includes Cytosponge, a swallowable capsule containing a compressed sponge attached to a string. When withdrawn, the sponge contains esophageal cytology samples that can be used to identify biomarkers for BE.

In a guideline released last spring, the American College of Gastroenterology endorsed Cytosponge as a nonendoscopic BE screening modality, as published in the American Journal of Gastroenterology.

“The strength of the recommendation is conditional, but it’s the first time where [the ACG] is saying that this may be an option for people,” Dr. Gross said.

This research was funded by the American College of Gastroenterology. Dr. Kolb, Dr. Gross, and Dr. Iyer report no relevant financial relationships.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Novel YouTube study detects colonoscopy misinformation, guides better content creation
MDedge Internal Medicine
Latiglutenase reduces symptoms in celiac patients exposed to gluten
MDedge Internal Medicine
Major U.S. GI societies issue strategic plan on environmental sustainability
MDedge Internal Medicine
NAFLD progresses to cirrhosis in young and old at similar rate
MDedge Internal Medicine
Dupilumab improves eosinophilic esophagitis up to 24 weeks
MDedge Internal Medicine
Guselkumab induction improves moderate to severe active UC at week 12
MDedge Internal Medicine
Endoscopic severity score helps guide treatment in immune-mediated colitis
MDedge Internal Medicine
Oral FMT on par with colonic FMT for recurrent C. difficile
MDedge Internal Medicine
‘Unappreciated’ ties between COVID and gut dysbiosis
MDedge Internal Medicine
FDA rejects bulevirtide for hepatitis D
MDedge Internal Medicine